UNSPSC 51382403: Bromfenac sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate but more generally known as bromfenac sodium, which bears US NIH Compound Identifier 60725. European Medicines Agency schedules Bromfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00874MIG.

UNSPSC 51382403 Bromfenac sodium is a Commodity code that in practice covers a narrow pharmaceutical product category, though recent state and local solicitations show little direct procurement activity aligned with the code's nominal scope. The code nominally identifies a nonsteroidal anti-inflammatory drug (NSAID) used primarily in ophthalmic settings, yet the three most recent opportunities tagged to this code involve broader pharmaceutical procurement — naloxone and drug deactivation systems, therapeutic pharmacy initiatives with direct-to-manufacturer distribution models, and generic multi-source pharmaceuticals with over-the-counter products. These misalignments suggest that state and local procurement offices are using this code as a catch-all pharmaceutical or health-supply classification rather than restricting it to bromfenac sodium specifically. Issuing bodies include county health systems (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). Activity reflects a mix of direct county procurement, state-level market research through RFI vehicles, and cooperative purchasing frameworks that aggregate demand across jurisdictions.

Activity spans Florida, Texas, Minnesota, and Oregon based on recent opportunities. The most concrete solicitation is Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building — a straightforward supply contract unrelated to bromfenac sodium. Texas HHS issued RFI HHS0017013 (April 3, 2026) as an exploratory market-research vehicle to assess vendor capabilities for direct-to-manufacturer prescription programs rather than a competitive solicitation for a specific drug. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP (January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026. The code's nominal scope and the actual work being solicited diverge substantially, signaling either systematic miscoding by state and local procurement offices or a data quality issue in how opportunities are tagged to the UNSPSC taxonomy.